Patents by Inventor Jonathan R. Keller

Jonathan R. Keller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeted recombinant viral vectors
    Publication number: 20030175973
    Abstract: The present invention provides methods and a composition for targeted delivery of a nucleic acid to a cell comprising a biotinylated recombinant encapsidated virus, particularly adenovirus, wherein the recombinant adenovirus comprises the nucleic acid, and wherein the biotinylated recombinant virus is linked via streptavidin to a biotinylated targeting moiety.
    Type: Application
    Filed: March 20, 2003
    Publication date: September 18, 2003
    Inventors: Sally E. Spence, Jeffrey S. Smith, Jonathan R. Keller
  • Complex of biotinylated viral vector and ligand for targeted gene delivery
    Patent number: 6555367
    Abstract: The present invention provides a composition for targeted delivery of a nucleic acid to a cell comprising a biotinylated recombinant adenovirus, wherein biotin is covalently linked to the recombinant adenovirus, wherein the recombinant adenovirus comprises the nucleic acid, and wherein the recombinant adenovirus is linked via streptavidin to a biotinylated targeting moiety. Also provided by this invention is a method for targeted delivery of a nucleic acid to a selected cell in a subject comprising administering to the subject a composition comprising a biotinylated recombinant adenovirus, wherein biotin is covalently linked to the recombinant adenovirus, wherein the recombinant adenovirus comprises the nucleic acid, and wherein the recombinant virus is linked via streptavidin to a biotinylated targeting moiety that specifically targets the selected cell.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: April 29, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Sally E. Spence, Jeffrey S. Smith, Jonathan R. Keller
  • Method for protecting bone marrow against chemotherapeutic drugs using transforming growth factor beta 1
    Patent number: 5278145
    Abstract: The present invention relates to a method for protecting hematopoietic stem cells from the myelotoxicity of chemotherapeutic drugs or radiation therapy, which comprises, administering to a subject a therapeutically effective amount of transforming growth factor beta 1 for protecting bone marrow from the myelotoxicity of chemotherapeutic drugs or radiation therapy. The TGF.beta.1 may be administered prior (e.g. 24 hours) to the administration of the chemotherapeutic drugs or radiation therapy. Preferably, the TGF.beta.1 is administered to the subject in an amount of about 5 .mu.g to 25 .mu.g per kg body weight. The patient or subject of the present invention may be a mammal (e.g. human, domestic animal such as horse, cow, dog, cat or pig) and is preferably a human being. The mode of administration is either by interfemoral arterial, interperitoneally or subcutaneously, and preferably is by injection.
    Type: Grant
    Filed: January 7, 1992
    Date of Patent: January 11, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jonathan R. Keller, Francis W. Ruscetti, Robert Wiltrout